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1. Introduction 
With its strict dependence on a continuous supply of oxygen and glucose to meet its energy 
needs and its high metabolic rate, the brain is particularly sensitive to any compromise of 
blood supply. Brain ischemia, as occurs in a number of disease states but most importantly 
in ischemic stroke and during cardiac arrest, rapidly results in exhaustion of ATP, triggering 
an energy crisis. Within minutes, the failure of ion pumps sees the depolarisation of 
neuronal cell membranes and the consequent release of stored presynaptic glutamate, 
leading, by way of overstimulation of glutamate receptors (=excitotoxicity), to many-fold 
increases in intracellular calcium and zinc concentrations. Severely affected cells die within 
only a few minutes. In those cells that are less severely injured, ongoing cellular and tissue 
damage occurs due to activation of proteolytic enzymes, oxidative and nitrosative stress 
(Forder & Tymianski, 2009), altered calcium homeostasis, initiation of active cell death 
pathways (apoptosis, necrosis, autophagy and necroptosis), inflammation (microglia and 
astrocyte activation, neutrophil infiltration within 4 - 6 hours), cortical spreading 
depressions, disruption of the blood brain barrier (BBB; starting at 2 hours, followed by a 
second phase from 24 - 72 hours; Brouns & De Deyn, 2009), microvascular injury (which 
promotes BBB disruption, inflammation and impairs vascular control of blood flow), 
hemostatic activation (platelet activation and the intrinsic pathway) and edema. 
Additionally, though reperfusion is the cornerstone of treatment, when/if it is established, 
many of these damaging events can be exacerbated.  
These processes are interconnected, rather than sequential, and presenting them as a list 
might be misleading if it were to be taken that counteracting one event would therefore 
prevent those occurring later in the list, even if they do in fact occur later in time. The list 
only acts as a summary of the damaging events, against which can be checked the likelihood 
of a potential therapy to do some good. The importance of each process waxes and wanes at 
different times during and after the ischemic episode, so an important principle of effective 
therapy is that it will need to be applied at the time of the injurious events to counteract its 
effect. In many respects hypothermia is, in theory, the ideal therapy, with multiple 
mechanisms of action in opposition to the consequences of ischemia.  
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2. Background of therapeutic hypothermia  
Cooling of the body for therapeutic purposes is not a new concept in medicine. For example, 
in 1941 the British Medical Journal noted that generalised therapeutic hypothermia was 
under investigation for the treatment of various cancers, such as bladder carcinoma 
(Anonymous, 1941). It was also suggested that whole body cooling might find use in 
patients with intractable pain, morphine addiction, leukaemia, and schizophrenia, though 
no mention was made at this time of stroke or cardiac arrest. In the early 1950s, however, 
studies were being performed in which animals were cooled to very low temperatures (16 - 
19ºC in macacus rhesus monkeys, 2.5 - 5ºC in groundhogs) to permit cardiac surgery 
(Bigelow & McBirnie, 1953). Cardiac output was completely stopped in these experiments 
for long periods (15 - 24 minutes in the monkeys, 1 - 2 hours in the groundhogs) with few 
deaths, and no apparent neurological deficits when the animals were recovered.  
Thus, it has been known for several decades at least that a state of hypothermia decreases 
central neurological injury in the face of ischemia. This has led to many animal studies, of 
various designs, which have tended to confirm the potential for hypothermia to reduce 
ischemic brain damage (for review see Meloni et al., 2008). In recent years, clinical trials 
have proven that moderate hypothermia, using a target body temperature of 33ºC, improves 
outcomes for cardiac arrest survivors (Bernard et al., 2002; Hypothermia after cardiac arrest 
study group, 2002; Meloni et al., 2008), and its use is, at the time of writing, under 
investigation in several ongoing or planned trials following ischemic and hemorrhagic 
stroke (Table 1; Meloni et al., 2008). Between them, these studies will answer several of the 
important questions regarding the best use of therapeutic hypothermia. 
 
Study* Method of cooling Number 
of 
subjects
Delay from 
stroke onset 
Tempe-
rature 
Duration 
Cerebral hypothermia 
in ischemic lesion 
(CHIL). Stroke Trials 
Directory 
Cold infusion 
induction + 
endovascular 
cooling or local 
head cooling  
 
80 Within 6h 
 
33°C 
 
24h 
 
Cooling in acute 
stroke-II (COAST-II). 
Stroke Trials Directory
Cold infusion 
induction + 
endovascular 
cooling# 
50 Within 3h; 30 
- 90min after 
tPA 
 
35°C 
 
24h 
 
Mild hypothermia in 
acute ischemic stroke 
(MHAIS) Stroke Trials 
Directory 
 
Surface cooling# 
 
36 Within 6h 
 
35°C 
 
12h 
 
Mild hypothermia in 
acute ischemic stroke 
trial – Edinburgh 
(HAIST-E). EUROHYP
 
Cold infusion 
induction + surface 
cooling# 
 
24 Within 4.5h 
 
35 or 33°C 
 
12 or 24h 
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Study* Method of cooling Number 
of 
subjects
Delay from 
stroke onset 
Tempe-
rature 
Duration 
Cooling for ischemic 
stroke trial  
(COOLIST);  
NTR2616.  
Nederlands Trial 
Register 
 
 
Cold infusion 
induction + surface 
cooling# 
 
84 Within 4.5h 
 
35, 34.5  
or 34°C 
24h 
 
Mild hypothermia in 
acute ischemic stroke 
(MASCOT; Pilot). 
EUROHYP 
 
 
Surface cooling 
 
40 Within 24 33°C 
 
24h 
 
Mild hypothermia in 
acute ischemic stroke: 
surface. vs 
endovascular cooling 
(HAIS-SE). Stroke 
Trials Directory 
 
 
Cold infusion 
induction; surface 
or endovascular 
cooling # 
 
60 Within 4.5h; 
30min after 
tPA 
 
34°C 
 
12, 18 or 
24h 
 
Cooling in 
intracerebral 
hemorrhage  
(CINCH).  
EUROHYP 
 
 
Endovascular 
cooling 
50 Within 6 - 18h
 
35°C 
 
8 d 
 
Hypothermia for 
intracerebral 
hemorrhage. 
Clinical Trials 
 
Surface cooling 20 Within 6h 
 
34°C 
 
24h 
 
European stroke 
research network for 
hypothermia 
(EuroHYP). EUROHYP
 
Cold infusion 
induction + surface 
or endovascular 
cooling# 
 
1500 Within 6h; 
within 90min 
after tPA 
 
34 - 35°C 
 
24h 
 
* For more detail see Stroke Trials Directory, EUROHYP Nederlands Trial Register and Clinical Trials 
web sites (details provided in reference list). # Patient awake and treated with pethidine and/or 
buspirone to control shivering and improve comfort. 
Table 1. Current clinical trials of hypothermia in stroke (ischemic and hemorrhagic). 
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3. Neuroprotective mechanisms of hypothermia 
There is evidence that therapeutic hypothermia has beneficial effects by numerous 
mechanisms including reduction of metabolic rate, promotion of energy recovery after 
ischemia, inhibition of glutamate release, inhibition of cell death pathways, inhibition of free 
radical formation, inhibition of inflammation, preservation of the BBB, stimulation of 
neurotrophin expression, and numerous effects on molecular responses to ischemia (e.g., 
inhibition of AMPK and MAPK activation, inhibition of SMAC/Diablo, p53).  
Intuitively, a reduced metabolic rate might be expected to be one of the more important 
means by which hypothermia could protect against ischemia, and it does make a 
contribution, though the effect is easily overestimated. It has been calculated that, on the 
measure of reduced metabolic oxygen consumption, 5 minutes of ischemia at 37ºC would 
cause approximately equivalent damage to 15 minutes of ischemia at 27ºC (Schaller & Graf, 
2003). Thus, the benefit is only moderate even at substantially lower temperatures than are 
usually considered suitable for most therapeutic purposes. There is evidence, however, that 
hypothermia also expedites the recovery of ATP stores after a period of ischemia, as well as 
improving the return of energy metabolism to pre-ischemic levels (Erecinska et al., 2003; 
Zhao et al., 2007). The combination of reduced demand and improved recovery both during 
and after what is a state of failed energy supply is perhaps enough to explain the 
outstanding neuroprotection afforded by intraischemic hypothermia. That is, without taking 
into account any of its other actions, hypothermia reduces the severity of any one incidence 
of cerebral ischemia. Its influence does not end there, however, though clearly hypothermia 
will necessarily be less effective when delayed. 
While excitotoxicity, principally attributable to overstimulation of the NMDA subtype of 
glutamate receptor, is a critical component of the ischemic cascade, its very early occurrence 
means it is likely to remain a frustrating target for therapeutic intervention. That said, there 
is fair evidence that hypothermia reduces, or at least delays, the release of glutamate from 
ischemic neurons, probably by delaying the onset of anoxic depolarisation (Zhao et al., 
2007). Using a cardiac arrest model, it was shown that hypothermia (31ºC/20min) either 
during ischemia or initiated at the time of reperfusion reduced extracellular glutamate 
concentrations (measured at the hippocampus), but not when the initiation of hypothermia 
was delayed by as little as 5 minutes after reperfusion (Takata et al., 2005). Hachimi-Idrissi 
et al. (2004) found a long lasting (more than 2 hours) inhibition of both glutamate and 
dopamine release in hypothermia (34°C/1h) treated animals when commenced after 
resuscitation in an asphyxiation/cardiac arrest model.  
Importantly, the activity of hypothermia in reducing oxidative damage after ischemia or 
ischemia-like insults is well-supported. Shin et al. (2010) found that, in rats, the death of 
neurons induced by hypoglycemia could be reduced by maintaining brain temperature at  
33 - 34ºC for 1 hour, and that this was associated with reductions in zinc ion 
release/translocation, generation of ROS, and activation of microglia. Maier et al. (2002) 
reported that intra-ischemic hypothermia (33°C/2h) reduced production of the superoxide 
anion after transient focal cerebral ischemia, and Van Hemelrijck et al. (2005) showed that 
hypothermia (34°C/2h during ischemia) reduced hydroxyl radical formation, by inhibition 
of neuronal NOS, during the resuscitative phase after focal cerebral ischemia.  
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There is general agreement from several studies that hypothermia improves membrane 
stability, reducing disruption of the BBB as well as protecting neuronal cell membranes. 
Kiyatkin and Sharma, 2009, found that hypothermia at 34 - 35ºC in normal brains slightly 
increased BBB permeability to albumin (compared to normothermia), but this did not result 
in edema. The mechanism appears to be related to temperature dependent variations in the 
sodium and chloride content of brain tissue, such that hypothermia reduces these ions by an 
undescribed mechanism, preventing osmotic draw into this tissue and producing a relative 
dehydration. In any case, the effect was mild, certainly compared to hyperthermia, which 
markedly increased both BBB permeability and edema. Baumann et al. (2009) found, on the 
other hand, that after global ischemia hypothermia (32ºC/6h commencing after reperfusion) 
stabilised blood vessels and decreased BBB permeability, probably by preservation of the 
basement membrane. Nagel et al. (2008) measured extravasation of MRI contrast agent after 
transient focal ischemia (tMCAO), and found that hypothermia (33ºC/4h starting 60min into 
90min MCAO) greatly reduced BBB disruption. Huang et al. (1999) showed that 
hypothermia (29°C/6h commencing after reperfusion) particularly reduces the second 
phase of BBB disruption that occurs around 24 hours after transient focal ischemia.  
Besides these non-specific harmful processes, there are in the penumbra a variety of pro-
apoptotic responses to ischemia that are mediated by particular molecular pathways. 
Identifying these pathways and investigating interventions to counteract them is a field of 
substantial current activity. There is too much to summarise here, and any such attempt 
would be likely to be out of date very soon. Nevertheless, a couple of examples are useful to 
give the flavour of the work being done, but for more additional information see recent 
reviews by Zhao et al. (2007) and González-Ibarra et al. (2011). 
AMP-activated protein kinase (AMPK) is responsive to energy stress, and, when 
phosphorylated, suppresses anabolic and promotes catabolic activity, evidently in order to 
maintain ATP supplies. Perhaps paradoxically, AMPK inhibition reduces ischemic brain 
damage, and there is evidence that hypothermia (32ºC/6h commencing after reperfusion) 
inhibits AMPK activation after transient focal cerebral ischemia in mice (Li et al., 2011). Li & 
Wang (2011) demonstrated that hypothermia (33ºC during transient focal ischemia) reduced 
expression of the protein complex second mitochondrion-derived activator of caspases 
(SMAC), an important molecule in the activation of apoptosis, which is upregulated in 
response to a variety of insults. The reduction in SMAC expression was also associated with 
reduced neurological impairment in rats after focal ischemia.  
4. Hypothermia and glial cells  
The best neurological outcomes will be achieved by measures taken to address the 
consequences of ischemia not just in neurons and the BBB, but in glial cells as well. Studies 
of the effects of hypothermia on glia are relatively few, but those there are suggest that 
hypothermia promotes survival and inhibits pathological responses in microglia and 
astrocytes. Hypothermia does reduce activation and proliferation of microglia, thus 
reducing oxidative and nitrosative stress (Si et al., 1997). Reduced activation of microglia 
associated with hypothermia has been demonstrated by several studies using different 
animal models, for example, during and after global cerebral ischemia (Kumar and Evans, 
1997; Webster et al., 2009), after transient focal cerebral ischemia (Inamasu et al., 2000), and 
after hypoxia/ischemia (Fukui et al., 2006). Hachimi-Idrissi et al. (2004) found that astrocyte 
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proliferation is also inhibited by hypothermia after asphyxiation/cardiac arrest and 
resuscitation. Haun et al. (1993) found that astrocyte cultures were made relatively resistant 
to an in vitro glucose-oxygen deprivation injury by hypothermia.  
5. Depth of hypothermia 
The efficacy of hypothermia increases as the depth of hypothermia increases, though the 
response is not linear. In a large meta-analysis of animal studies, van der Worp et al. (2007) 
found that the greatest therapeutic response (reducing mean infarct volumes by 
approximately 55%) was achieved by cooling to below 30ºC, though cooling to even 35ºC, 
the highest level of hypothermia included, still resulted in a considerable positive response 
(infarct volume reduction of 30%). What’s more, the adverse effects of the treatment 
(specifically cardiac arrhythmias, coagulopathies and immunosuppression) also increase 
with increasing depth, as do the technical difficulties involved in bringing patients to deeper 
body temperatures in the first place. Therefore, the optimum target will be the best balance 
between therapeutic effect versus detrimental effect versus practicality. While the optimum 
target temperature is still to be determined, based on preclinical and clinical studies it will 
probably be in the range 33 to 35ºC, that is, what is usually referred to as moderate or mild 
hypothermia. As mentioned earlier hypothermia at 33°C is being used following cardiac 
arrest in comatose survivors admitted to intensive care wards. However, from a clinical 
standpoint, hypothermia of 35°C offers the advantage of being achievable in awake subjects 
outside of intensive care units, which would comprise the majority of stroke patients. 
Furthermore several of the ongoing and planned stroke trials listed in Table 1 will provide 
data that aims to specifically address the question of the relative efficacy of hypothermia at 
33°C versus 35°C.  
It is worth considering here the use of hypothermia during (when it is most effective) 
cardiothoracic and neurosurgical procedures, in which body temperatures are lowered from 
anywhere from 26 - 35°C, specifically to protect tissues, including the brain, during an 
anticipated period of compromised blood supply. For example during cardiac surgery, there 
are two distinct levels of hypothermia that are commonly used; a target body temperature of 
34 - 35ºC is now becoming accepted as the standard for Cardiopulmonary Bypass (CPB), 
while in especially critical cases surgeons may opt to use Deep Hypothermic Circulatory 
Arrest (DHCA) in which patients are cooled to a rather extreme 15 - 26ºC (Choi et al., 2009; 
Cook, 2009; Mackensen et al., 2009).  
6. Timing and duration of hypothermia 
As noted earlier, the pathophysiology of cerebral ischemia is dynamic and multifaceted, 
with numerous damaging mechanisms occurring, becoming important at different times, 
and lasting for different durations, many of which interact to exacerbate the effect of 
another. It is an oversimplification to say that hypothermia reduces the impact of all of these 
damaging processes, but it’s fair to say that that is the trend. Consequently, the earlier 
hypothermia is commenced and the longer it is maintained while the ischemic damaging 
processes are occurring will permit the greatest neuroprotective effect. This contention is, 
however, not particularly well borne out by the evidence from animal trials (van der Worp 
et al., 2007), though there are some possible reasons for this finding (van der Worp et al., 
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2010). In the bulk of animal trials, hypothermic treatment is used during or very soon after 
ischemia, when it is most effective. Prolonging hypothermia in this situation allows little 
opportunity to improve on the highly effective neuroprotection afforded by early treatment, 
while permitting the adverse effects of hypothermia treatment (eg. coagulopathies, 
immunosuppression, pneumonia) to become significant. Furthermore, there will be a time 
after ischemia where delayed hypothermia will not be effective at inhibiting 
neuroregenerative processes. There is evidence, however, that the longer treatment is 
delayed, short periods of hypothermia have little or no effect, while prolonged hypothermia 
(>24h) can be very effective (Clark et al., 2008; Colbourne et al., 1999ab; Zhu et al., 2005).  
Again, however longer treatment consumes more resources and also increases the health 
risks, particularly in patients who require sedation or anaesthesia to maintain the 
hypothermic state. The optimum duration of hypothermia will most likely be in the range 12 
- 48 hours, and is likely also to be dependent on factors such as the specific cause of ischemia 
(stroke, cardiac arrest), severity of ischemia, age of patient and the time delay to 
commencing hypothermia after ischemia. In terms of therapeutic window, this will vary 
depending on the type of ischemia (focal vs global) and severity, but could be up to 6 hours 
following stroke (focal ischemia; Ohta et al., 2007) and up to 12 hours following global 
ischemia (Colbourne et al., 1999b; Coimbra & Walsh, 1994). With respect to rewarming it is 
becoming increasingly accepted that slow rewarming at the rate of 0.2 - 0.3°C/hour is most 
desirable (Bardutzky & Schwab, 2007; Bernard & Buist, 2003).  
7. Cooling methods  
One of the most significant barriers to therapeutic hypothermia is the technical difficulty 
involved in inducing the target temperature in the target tissue in a timely and safe manner. 
Large mammals such as humans are very efficient at maintaining a normal body 
temperature in the face of attempts to cool the body. Available techniques are surface 
cooling by refrigerative blankets, cooling helmets, cold air blowers, intravascular heat 
exchangers, intravascular cold fluids and, which is currently under investigation, intranasal 
evaporative cooling (Castrén et al., 2010; Jordan & Carhuapoma, 2007). An alternative 
approach is the use of pharmaceutical agents, such as the neurotensin analogue NT77 to 
alter the body’s temperature set-point as monitored and controlled by the hypothalamus, 
thus allowing an effectively physiological induction of hypothermia (Katz et al., 2004). Each 
of these has advantages and disadvantages in cost, accuracy, degree of control, rate of 
cooling and ease of application. Mild hypothermia can be induced in awake patients, as long 
as steps are taken to manage the associated discomfort (see below), but moderate to deep 
hypothermia requires sedation or anaesthesia with intubation, ventilation and intensive care 
measures.  
At present the intravenous infusion of cold salt solutions (4°C) at a rate of 20 - 30ml/kg over 
20 - 30 minutes is gaining acceptance as the method of choice to induce hypothermia 
(Bernard et al., 2003; Polderman et al., 2005; Moore et al., 2008). The cold saline infusion 
procedure has several attractions as it is: i) inexpensive ii) safe; iii) relatively straight 
forward; iv) fast at inducing mild to moderate hypothermia (33 - 35°C); v) applicable in the 
field allowing early hypothermia induction; vi) suited for use in both comatose and awake 
subjects; and vii) often indicated anyway as a means of improving physiological parameters 
(blood pressure, renal function, acid-base homeostasis; Bernard et al., 2003). Following 
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hypothermia induction by cold saline infusion one or more of the cooling procedures 
outlined above would then be implemented to provide a more precise control of body 
temperature. 
To further aid the induction and maintenance of hypothermia the use of pethidine 
(meperidine) alone or with other agents, such as, the anxiolytic buspirone or magnesium are 
being used (Kliegel et al., 2007; Mokhtarani et al., 2001; Martin-Schild et al., 2009; Zweifler et 
al., 2004; Table 1). The use of these agents, along with simple measures such as warm gloves 
and socks is especially useful when inducing hypothermia in awake patients to minimize 
discomfort and shivering (Mahmood & Zweifler, 2007). 
8. Combination with other treatments  
A substantial advantage of hypothermia is that it presents little or no obstacle to the 
application of other treatments, and in fact has been shown to enhance or act synergistically 
with some other neuroprotective approaches (Campbell et al., 2008; Zhu et al., 2005). In 
reviewing the literature, we have found that hypothermia in combination treatments 
generally has additive or synergistic effects, and in several instances medications which 
were thought to be neuroprotective were later found to induce hypothermia and in fact 
were not neuroprotective at all when normal body temperatures were maintained 
(Campbell et al., 2007; Nurse & Corbett, 1996). It is especially important that any potential 
stroke treatment should be compatible with tPA thrombolysis, and in this respect it appears 
based on in vitro data that at least for mild hypothermia (i.e. 35°C), it will not significantly 
reduce the effectiveness of tPA (Schwarzenberg et al., 1998; Shaw et al., 2007; Yenari et al., 
1995). 
9. Concluding remarks  
There is compelling experimental and clinical evidence that mild to moderate hypothermia 
is effective following global and focal (ischemic stroke) cerebral ischemia. However, it is 
likely that the depth and duration of hypothermia that provides the best benefit to patients 
will vary depending on the type (global vs focal) and severity of brain ischemia, the time 
that hypothermia is commenced, and patient age and presence of co-morbidities (diabetes, 
hypertension). Therefore further experimental and clinical trials will be required to 
determine hypothermia protocols that best suit individual patients. Moreover, based upon 
the available human studies, it appears that the use of hypothermia, in particular mild 
hypothermia (35°C) is feasible and safe to implement in clinical situations. In addition, 
based on current information therapeutic hypothermia should be commenced as soon as 
possible after the ischemic event, and maintained for durations of 12 - 48 hours to achieve a 
sustained benefit in terms of neuronal recovery and survival and functional benefits. To this 
end, future experimental studies in global and focal ischemia models and the results of the 
clinical stroke trials, will no doubt, help address further refinement of therapeutic 
hypothermia protocols to better suit individual cases. In addition, evaluation of the 
effectiveness of hypothermia in combination with other potential neuroprotective agents 
such as magnesium, caffeinol, glutamate antagonists and anti-oxidants could further 
improve efficacy.  
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